GlassScriptPhysician profile
Brenden Ingraham
NPI 1497284616
$6,141.78
in general payments reported to CMS, 2019-2025
11 companies · $341 in 2025
The $341 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $360 · 2023: $116 · 2024: $5,325 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,934 · Food and Beverage: $2,848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,933.85 |
| Food and Beverage | $2,848.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $2,125.96 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Penumbra, INC. | $1,461.60 | 2022-2024 | Indigo System |
| Medtronic, INC. | $1,238.51 | 2024 | Venaseal, Turbohawk |
| Abbott Laboratories | $311.43 | 2024-2025 | Esprit |
| Abiomed | $281.71 | 2022-2024 | Impella |
| Biotronik INC. | $238.78 | 2024 | Pulsar-18 T3, Passeo-18 |
| Boston Scientific Corporation | $195.37 | 2023-2024 | |
| Stryker Corporation | $124.37 | 2025 | Flowtriever, Limflow System |
| Teleflex LLC | $80.86 | 2025 | Pulsar-18 T3 |
| Cagent Vascular INC | $65.27 | 2024 | Serrantor |
| Edwards Lifesciences Corporation | $17.92 | 2024 | Sapien 3 Ultra Resilia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brenden Ingraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.